News & Updates
Filter by Specialty:

Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
16 Nov 2021
byStephen Padilla
The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.